Box Behnken design of siRNA-loaded liposomes for the treatment of a murine model of ocular keratitis caused by Acanthamoeba

Zorzi, Giovanni K.; Schuh, Roselena Silvestri; Maschio, Vinícius José; Brazil, Nathalya Tesch; Rott, Marilise Brittes; Teixeira, Hélder Ferreira

doi:10.1016/j.colsurfb.2018.10.044

Cited by 28 publications

(14 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combined therapy of siRNA-loaded polymeric vesicles with chlorhexidine led to a 60% reduction in corneal damage caused by Acanthamoeba in a 2 month-old Wistar rat model. 87 Further studies should be performed to confirm the effectiveness of this treatment.…”

Section: Keratitismentioning

confidence: 98%

Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective

Zhang¹,

Jiao²,

Niu³

et al. 2021

IJN

View full text Add to dashboard Cite

The complex drug delivery barrier in the eye reduces the bioavailability of many drugs, resulting in poor therapeutic effects. It is necessary to investigate new drugs through appropriate delivery routes and vehicles. Nanotechnology has utilized various nano-carriers to develop potential ocular drug delivery techniques that interact with the ocular mucosa, prolong the retention time of drugs in the eye, and increase permeability. Additionally, nano-carriers such as liposomes, nanoparticles, nano-suspensions, nano-micelles, and nano-emulsions have grown in popularity as an effective theranostic application to combat different microbial superbugs. In this review, we summarize the nano-carrier based drug delivery system developments over the last decade, particularly review the biology, methodology, approaches, and clinical applications of nano-carrier based drug delivery system in the field of ocular therapeutics. Furthermore, this review addresses upcoming challenges, and provides an outlook on potential future trends of nano-carrier-based drug delivery approaches in ophthalmology, and hopes to eventually provide successful applications for treating ocular diseases.

show abstract

Section: Keratitismentioning

confidence: 98%

Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective

Zhang¹,

Jiao²,

Niu³

et al. 2021

IJN

View full text Add to dashboard Cite

show abstract

“…In most cases, the modification was carried out by the introduction of a PEGylated unit in the vesicle outer surface, since they have demonstrated improved penetration levels, better bioavailability and reduced toxicity compared to non-modified vesicles [ 64 ]. In this sense, Zorzi et al [ 65 ] developed a PEGylated PV to encapsulate siRNA sequences for the treatment of ocular keratitis caused by Acanthamoeba . A combined therapy of siRNA-loaded PV with chlorhexidine led to a 60% reduction in corneal damage caused by this disease in a murine model.…”

Section: Polymeric Nanocarriers For Ocular Drug Deliverymentioning

confidence: 99%

Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects

et al. 2020

View full text Add to dashboard Cite

The complexity of some diseases—as well as the inherent toxicity of certain drugs—has led to an increasing interest in the development and optimization of drug-delivery systems. Polymeric nanoparticles stand out as a key tool to improve drug bioavailability or specific delivery at the site of action. The versatility of polymers makes them potentially ideal for fulfilling the requirements of each particular drug-delivery system. In this review, a summary of the state-of-the-art panorama of polymeric nanoparticles as drug-delivery systems has been conducted, focusing mainly on those applications in which the corresponding disease involves an important morbidity, a considerable reduction in the life quality of patients—or even a high mortality. A revision of the use of polymeric nanoparticles for ocular drug delivery, for cancer diagnosis and treatment, as well as nutraceutical delivery, was carried out, and a short discussion about future prospects of these systems is included.

show abstract

“…It was also proposed that a combination of two gene-specific siRNAs (one targeting serine proteases and one targeting glycogen phosphorylase) could affect the growth rate and survival of amoeba [94]. Later, Zorzi et al [95] designed siRNA-loaded liposomes for the successful treatment of a murine model of ocular keratitis caused by Acanthamoeba, further highlighting siRNAs as a promising future therapeutic approach.…”

Section: Sirna-based Therapeuticsmentioning

confidence: 99%

Drug Discovery against Acanthamoeba Infections: Present Knowledge and Unmet Needs

2020

View full text Add to dashboard Cite

Although major strides have been made in developing and testing various anti-acanthamoebic drugs, recurrent infections, inadequate treatment outcomes, health complications, and side effects associated with the use of currently available drugs necessitate the development of more effective and safe therapeutic regimens. For any new anti-acanthamoebic drugs to be more effective, they must have either superior potency and safety or at least comparable potency and an improved safety profile compared to the existing drugs. The development of the so-called ‘next-generation’ anti-acanthamoebic agents to address this challenge is an active area of research. Here, we review the current status of anti-acanthamoebic drugs and discuss recent progress in identifying novel pharmacological targets and new approaches, such as drug repurposing, development of small interfering RNA (siRNA)-based therapies and testing natural products and their derivatives. Some of the discussed approaches have the potential to change the therapeutic landscape of Acanthamoeba infections.

show abstract

Box Behnken design of siRNA-loaded liposomes for the treatment of a murine model of ocular keratitis caused by Acanthamoeba

Cited by 28 publications

References 35 publications

Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective

Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective

Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects

Drug Discovery against Acanthamoeba Infections: Present Knowledge and Unmet Needs

Contact Info

Product

Resources

About